An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States

In this commentary, the authors propose new approaches for triaging, pricing, and financing that can reduce the costs of gene therapy, improve patient access, and address the historical neglect of patients with sickle cell disease.